引起
发表于 2025-3-23 10:37:37
http://reply.papertrans.cn/79/7809/780823/780823_11.png
Medley
发表于 2025-3-23 14:47:51
http://reply.papertrans.cn/79/7809/780823/780823_12.png
清真寺
发表于 2025-3-23 19:06:38
http://reply.papertrans.cn/79/7809/780823/780823_13.png
condemn
发表于 2025-3-24 00:00:32
http://reply.papertrans.cn/79/7809/780823/780823_14.png
作呕
发表于 2025-3-24 03:13:57
http://reply.papertrans.cn/79/7809/780823/780823_15.png
wall-stress
发表于 2025-3-24 10:07:50
The Parallel Between Clinical Trials and Diagnostic Tests,fference between statistical power and the probability of a positive trial. This last point becomes more important as a new drug moves through the various development stages as will be illustrated in Chap. 9.
jeopardize
发表于 2025-3-24 10:56:35
Incorporating Information from Completed Trials in Future Trial Planning,ities under some definitions of success. We can use simulations to estimate these probabilities when close-form expressions do not exist. With the use of prior distributions for the parameters of interest, we show how to assess the positive and negative predictive values of a design with its companion decision rule.
勉励
发表于 2025-3-24 15:07:59
http://reply.papertrans.cn/79/7809/780823/780823_18.png
磨坊
发表于 2025-3-24 22:21:30
Designing Phase 4 Trials,o consider a trial comparing a drug against a comparator using information obtained from the network meta-analysis. We also discuss how prior distributions for treatment effects may be obtained by other means such as PK/PD modeling.
Countermand
发表于 2025-3-25 01:42:41
http://reply.papertrans.cn/79/7809/780823/780823_20.png